CAPR
Capricor Therapeutics Sets Sights on Historic Approval for Groundbreaking Duchenne Muscular Dystrophy Treatment
In a major milestone for Capricor Therapeutics, the company has announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for Deramiocel, a treatment designed to address both skeletal and cardiac disease manifestations of Duchenne muscular dystrophy. The FDA has assigned a PDUFA